Oxford Vacmedix and Chain Biotech to Collaborate on Approach Using Live Biotherapeutics to Deliver Cancer Vaccines

Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today the award of an Innovate UK grant to CHAIN Biotech Ltd (CHAIN) and the University of Oxford to develop live biotherapeutics that support oral delivery for OVM’s recombinant overlapping peptide (ROP) cancer vaccines. The research will use CHAIN’s proprietary microbiome technology and the world-class research facilities in the University’s department of Oncology.